The invention described herein relates to the preparation of cellulosic foam products prepared from silver alginate and derivatives thereof and the process for preparing them. The silver alginate products and related silver products are amenable for use in the preparation of medical and veterinary d
The invention described herein relates to the preparation of cellulosic foam products prepared from silver alginate and derivatives thereof and the process for preparing them. The silver alginate products and related silver products are amenable for use in the preparation of medical and veterinary dressings for the treatment of burns, wounds, ulcerated lesions, and related pathological states.
대표청구항▼
The invention described herein relates to the preparation of cellulosic foam products prepared from silver alginate and derivatives thereof and the process for preparing them. The silver alginate products and related silver products are amenable for use in the preparation of medical and veterinary d
The invention described herein relates to the preparation of cellulosic foam products prepared from silver alginate and derivatives thereof and the process for preparing them. The silver alginate products and related silver products are amenable for use in the preparation of medical and veterinary dressings for the treatment of burns, wounds, ulcerated lesions, and related pathological states. growth hormone in the treatment of visceral fat accumulation in HIV infection: interim analysis" (1999). Abstract 336*/32173--Kotler et al., "Alterations in body fat distribution in HIV-infected men and women" 12 World AIDS Conference Geneva (Jun. 28-Jul. 3, 1998). Abstract 002--Muurahainen et al., "The SALSA (self-ascertained lipodystrophy syndrome assessment) cohort: abnormalities in cases compared to controls" (1999). Abstract 063--Muurahainen et al., "Abnormalities in HIV-associated lipodystrophy syndrome that vary by weight status" (1999). Abstract 177*/12373--Dong et al., "Changes in body habitus in HIV(+) women after initiation of protease inhibitor therapy" (1998). Carr et al., 5thConference on Retroviruses and Opportunistic Infections "A syndrome of peripheral lipodystrophy (LD), hyperlipidemia and Insulin resistance due to HIV protease inhibitors (PI's)", Chicago, IL, p. 410 (Feb. 1-6, 1998). Mulligan et al., 5thConference on Retroviruses and Opportunistic Infections "Evidence of unique metabolic effects of protease inhibitors", Chicago, IL, p. 414 (Feb. 1-5, 1998). Keruly et al., 5thConference on Retroviruses and Opportunistic Infections "Diabetes and hyperglycemia in patients receiving protease inhibitors", Chicago, IL, p. 415 (Feb. 1-5, 1998). Dong et al., 5thConference on Retroviruses and Opportunistic Infections "Diabetes and use of protease inhibitors", Chicago, IL, p. 416 (Feb. 1-5, 1998). Lo et al., "Buffalo hump" In men with HIV-1 infection, The Lancet, 351:867-870 (Mar. 21, 1998). Miller et al., "Visceral abdominal-fat accumulation associated with use of indinavir", The Lancet, 351:871-875 (Mar. 21, 1998). Viraben et al., "Indinavir-associated lipodystrophy", AIDS, 12:F37-F39 (1998). Adelman et al., "In vitro deletional mutagenesis for bacterial production of the 20,000-Dalton form of human pituitary growth hormone", DNA, 2:183-193 (1983). Albertsson-Wikland et al., "Daily subcutaneous administration of human growth hormone in growth hormone deficient children", Acta Poediatr Scand, 75:89-97 (1986). Becker et al., "Chemical physical, and biological characterization of a dimeric form of biosynthetic human growth hormone", Biotechnology and Applied Biochemistry, 9:478-487 (1987). Bewley et al., "The chemistry of human pituitary growth hormone", Adv. Emzymol, Related Areas, 42:73-166 (1975). Denoto et al., "Human growth hormone DNA sequence and mRNA structure: possible alternative splicing", Nucleic Acids Research, 9:3718-3731 (1981). Hendricks et al., "Plasma clearance of intravenously administered pituitary human growth hormone: gel filtration studies of heterogeneous components", Journal of Clinical endocrinology and Metabolism, 60:864-867 (1985). J.o slashed.rgensen et al., "Serum profiles and short-term metabolic effect of pituitary and authentic biosynthetic human growth hormone in man a double-blind cross-over study", Acta Endocrinologica (Copenh), 116:381-386 (1987). J.o slashed.rgensen et al., "Pharmacokinetics of biosynthetic and pituitary human growth hormones in rats", Pharmacology & Toxicology, 63:129-134 (1988). Lewis et al., "An interchain disulfide dimmer of human growth hormone*", The Journal of Biological Chemistry, 252:3697-3702 (1977). Lewis et al., "Enhancement of the hyperglycemic activity of human growth hormone by enzymic modification", Endo. 101:1587-1603 (1977). Lewis et al., "Human Growth hormone; additional members of the complex*", Endo, 104:1256-1265 (1979). Lewis et al., "Altered proteolytic cleavage of human growth hormone as a result of deamidation", The Journal Of Biological Chemistry, 256:11645-11650 (1981). Ho et al., "Indinavir-associated facial lipodystrophy in HIV-infected patients", AIDS Patient Care and STDs, 13:11-16 (1999). Kosmiski et al., "An increase in abdominal girth on protease inhibitor therapy is associated with visceral obesity and metabolic disturbances that closely resemble syndrome", 1
※ AI-Helper는 부적절한 답변을 할 수 있습니다.